

September 10, 2014



## Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences

SOUTH EASTON, Mass., Sept. 10, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: P BIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Rodman and Renshaw ("Rodman") and SeeThruEquity ("STE") Investment Conferences this week in New York City. Mr. Schumacher's presentation at Rodman is scheduled for Wednesday, September 10 at 12:05pm in the Palace Hotel. Mr. Schumacher's presentation at STE is scheduled for Thursday, September 11 at 9:00am at the Convene Times Square.

Mr. Schumacher's presentation at Rodman will be webcast and may be viewed live at the following link (<http://wsw.com/webcast/rrshq24/pbio>) and up to 90 days thereafter on the Company's website ([www.pressurebiosciences.com](http://www.pressurebiosciences.com)).

### About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: P BIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following website link: <http://www.pressurebiosciences.com>

Please Visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:	
Richard T. Schumacher, President and CEO	(508) 230-1828 (T)

Richard P. Thomley, CFO	(508) 230-1829 (F)
-------------------------	--------------------

SOURCE Pressure BioSciences, Inc.